Volume 12, Issue 2 (10-2020)
2020, 12(2): 52-56 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bigdeli A, Ghorbani Moghadam M, Afsharian M. Report of a Case of Immunoglobulin A Nephropathy in a Patient Without a Family History of Kidney Disease. North Khorasan University of Medical Sciences 2020; 12 (2) :52-56
URL: http://journal.nkums.ac.ir/article-1-2089-en.html
URL: http://journal.nkums.ac.ir/article-1-2089-en.html
1- Specialist in Kidney Diseases, Member of the Faculty of North Khorasan University of Medical Sciences, Bojnourd, Iran
2- Master’s Degree Student in Nursing, Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnourd, Iran ,ghorbani961531070@gmail.com
3- Pathologist of Mashhad University of Medical Sciences, Mashhad, Iran
2- Master’s Degree Student in Nursing, Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnourd, Iran ,
3- Pathologist of Mashhad University of Medical Sciences, Mashhad, Iran
Abstract: (2648 Views)
Introduction: IgA Nephropathy is the most common form of glomerulonephritis and the major cause of end-stage renal disease. Gross or microscopic hematuria is a common symptom of hematuria and occurs in less than 5% to 10% of patients with IGM with rapidly progressive glomerulonephritis. The aim of this study was to investigate the diagnostic biomarkers of this disease after biopsy.
Methods: IgA (N) Nephropathy is the most common glomerulonephritis in the world and is currently recognized as an important end-stage renal disease (ESRD). Hypertension, proteinuria greater than 1 g / day, and severe lesions in primary renal biopsies such as crescent and interstitial fibrosis are the major predictors of progression to ESRD. Despite its prevalence and clinical significance, there is no consensus for treating patients with risk factors for worse prognosis. Our aim is to describe cases of crescentic IgA N and emphasize the efficacy of immunosuppressive therapy here.
Results: This is a case-control study of the physiological and pathologic features of a patient with clinical, radiologic, and treatment modalities of a patient with immunoglobulin A nephropathy without a history of renal disease.
Conclusions: IgA Nephropathy, first identified nearly four decades ago as one of the types of kidney disease, is one of the most common causes of primary glomerulonephritis in developing countries and is now one of the major causes (End - stage renal disease (ESRD).
Methods: IgA (N) Nephropathy is the most common glomerulonephritis in the world and is currently recognized as an important end-stage renal disease (ESRD). Hypertension, proteinuria greater than 1 g / day, and severe lesions in primary renal biopsies such as crescent and interstitial fibrosis are the major predictors of progression to ESRD. Despite its prevalence and clinical significance, there is no consensus for treating patients with risk factors for worse prognosis. Our aim is to describe cases of crescentic IgA N and emphasize the efficacy of immunosuppressive therapy here.
Results: This is a case-control study of the physiological and pathologic features of a patient with clinical, radiologic, and treatment modalities of a patient with immunoglobulin A nephropathy without a history of renal disease.
Conclusions: IgA Nephropathy, first identified nearly four decades ago as one of the types of kidney disease, is one of the most common causes of primary glomerulonephritis in developing countries and is now one of the major causes (End - stage renal disease (ESRD).
Keywords: Nephropathy, Immunoglobulin A
Type of Study: Case Report |
Subject:
Basic Sciences
Received: 2020/02/29 | Accepted: 2020/06/13 | Published: 2020/10/1
Received: 2020/02/29 | Accepted: 2020/06/13 | Published: 2020/10/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
